Previous 10 | Next 10 |
home / stock / lly / lly articles
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 18.31% on an annualized basis producing an average annual return of 27.9...
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a rene...
Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and cond...
Eli Lilly And Co (NYSE: LLY) reportedly intends to construct a production plant in western Germany with an estimated investment of €2 bil...
Germany's Federal Institute for Drugs and Medical Devices (BfArM) is reportedly contemplating a potential export prohibition on Novo Nordi...
Pfizer Inc (NYSE: PFE) is turning its focus to the weight loss drug market, aiming to capture a $10 billion segment with its experimental obes...
Eli Lilly And Co's (NYSE: LLY) investigational RNA-directed drug lepodisiran lowered lipoprotein(a) levels in a Phase 1 study. Elevated le...
A clinical trial has revealed that Novo Nordisk's (NYSE: NVO) weight loss drug Wegovy significantly decreases the risk of serious heart complic...
CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors, spotlighting significant data and earni...
News, Short Squeeze, Breakout and More Instantly...
Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS , July 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2024 financial results on Aug. 8, 2024 ....
2024-07-24 06:39:00 ET If you're a dividend investor, you shouldn't bother with stocks that don't raise their payouts. Inflation has drastically chipped away at consumers' purchasing power in recent years, highlighting just how important it is for dividend income to rise over the long run...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...